China’s Hansoh Pharmaceutical Group , a Roche partner, reported a 27% rise in annual profit on Sunday, beating market expectations and boosted by income from innovative medicines and business development deals.
The specialist in oncology, anti-infective, central nervous system disease, metabolic disease and autoimmune disease drugs has expanded licensing deals and developed innovative medicines amid Beijing’s centralised bulk buying programmes, which ha… [436 chars]
Source: Reuters | Published: 2026-03-29T12:16:52Z
Credit: Reuters
